Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'

Benzinga_recent_news02-09

Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory. Check out other analyst stock ratings. Wedbush: Biogen ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610654781?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/09/Biogen-World-Headquarters-At-225-Binney-_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-02-09 23:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610654781","market":"us","top_or_hot":-1,"title":"Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'","media":"Benzinga_recent_news","content":"<div>\n<p>Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory.\nCheck out other analyst stock ratings.\nWedbush: Biogen ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50483940/biogen-posts-q4-beat-these-analysts-significant-pipeline-diversification\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-09 23:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50483940/biogen-posts-q4-beat-these-analysts-significant-pipeline-diversification><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory.\nCheck out other analyst stock ratings.\nWedbush: Biogen ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50483940/biogen-posts-q4-beat-these-analysts-significant-pipeline-diversification\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50483940/biogen-posts-q4-beat-these-analysts-significant-pipeline-diversification","article_id":"2610654781","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/09/Biogen-World-Headquarters-At-225-Binney-_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/02/50483940/biogen-posts-q4-beat-these-analysts-significant-pipeline-diversification","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610654781","pubTimestamp":1770652260,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Biogen reported its quarterly revenues and earnings ahead of expectations for both the fourth quarter and the full year 2025.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"百健(Biogen)第四季度业绩好于预期，分析师因“重大管道多元化”而提高价格目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory.\nCheck out other analyst stock ratings.\nWedbush: Biogen reported its quarterly revenues and earnings ahead of expectations for both the fourth quarter and the full year 2025, Chico said in a note. Although the management team did a commendable job in realigning the cost base, revenue growth drivers remain \"the critical missing piece for the turnaround story,\" she added.\nWhile newer products (Leqembi, Skyclarys, Zurzuvae, Qalsody) generated around $980 million in sales in 2025, management expects total sales to decline by about $500 million in 2026, \"as competitive/generic/biosimilar threats mount on the MS franchise,\" the analyst wrote. She further stated that Biogen does have a \"stronger\" catalyst lineup in 2026 than it had in prior years, including:\nHC Wainwright: Biogen will have \"significant pipeline diversification across renal, lupus, and SMA indications\" in 2026 and beyond, Fein said. \"While the company’s legacy multiple sclerosis franchise faces ongoing revenue pressure, we believe growth from key assets like Skyclarys, Zurzuvae, and Leqembi is expected to increasingly drive the top line,\" he wrote.\nThe felzartamab program for antibody-mediated rejection (AMR) is a \"major clinical catalyst\" that could significantly impact Biogen’s future valuation, the analyst stated. An analysis of the AMR program that felzartamab achieved an 82% resolution rate in Phase 2 compared to just 20% for placebo, he added.\nBIIB Price Action: Shares of Biogen had declined by 3.41% to $194.31 at the time of publication on Monday.\nImage: Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610654781","isCrawlerRequest":true}